VYNE Therapeutics Inc.
$28.56 +$3.11 (+12.22%) 1D Market openKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 24
From its Jul 23 high, the share price fell 45%.
Peak close $46.17 on Jul 23; trough close $25.45 on Jul 24. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -45% -
Jul 24
The stock moved -44.9% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jul 24 -
Jul 22
The stock moved +4927.4% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jul 22 -
Jul 21
A material event was filed (Form 8-K).
8-K - VYNE Therapeutics Inc. (0001566044) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE
The story updates itself as events post · The wolf reports; you decide
Snapshot
About VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.